Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nihon Rinsho ; 73(4): 661-5, 2015 Apr.
Artigo em Japonês | MEDLINE | ID: mdl-25936158

RESUMO

This paper reviews the sleep habit and sleep problems in Japanese women. Some nationwide surveys in Japan showed that average sleep duration of Japanese women has been decreasing in these years. Insomnia related with menopause, restless legs syndrome and sleep related breathing disorder are recognized in middle-aged women. Recent studies have provided evidence that these sleep disorders increase the occurrence of cardiovascular events or other comorbid physical disorders. It is important to promote health education on sleep hygiene and provide early interventions for insomnia.


Assuntos
Transtornos do Sono-Vigília , Depressão/complicações , Feminino , Humanos , Menopausa , Síndrome das Pernas Inquietas/complicações , Caracteres Sexuais , Transtornos do Sono-Vigília/epidemiologia , Transtornos do Sono-Vigília/etiologia
2.
Prog Neuropsychopharmacol Biol Psychiatry ; 36(2): 313-7, 2012 Mar 30.
Artigo em Inglês | MEDLINE | ID: mdl-22119746

RESUMO

Olanzapine has frequently been reported to induce substantial weight gain, which is associated with an increased prevalence of dyslipidemia and type 2 diabetes. Several reports have described that olanzapine orally disintegrating tablets (ODT) induce less weight gain than oral standard tablets (OST) do, although both forms have equal bioavailability. We tried to clarify whether or not body weight change differed between olanzapine ODT and OST treatments in olanzapine-naïve schizophrenia patients. An open-label, 12-month, multicenter, randomized, flexible-dose study was conducted for direct comparison of the effects of OST (mean dosage, 15.7 mg; N=57) and ODT (mean dosage, 15.2 mg; N=61) on body weight and metabolic measures such as blood glucose, hemoglobin(A1c), total cholesterol and HDL-cholesterol, and triglycerides in olanzapine-naïve patients with schizophrenia. Outcome measures included Positive and Negative Syndrome Scale (PANSS), Global Assessment of Function (GAF), The World Health Organization Quality of Life 26 (WHO-QOL26), Drug Attitude Inventory (DAI)-10, and tolerability assessed by the UKU side-effect rating scale. This study was conducted between June 2007 and April 2010. No significant difference was found in the weight gain between the two forms of olanzapine. No significant difference was found between the two groups in any metabolic measure, efficacy, tolerability, WHO-QOL26, or DAI-10 score. Previous reports describing that olanzapine ODT induced less weight gain than OST were not supported by results of this randomized study.


Assuntos
Benzodiazepinas/administração & dosagem , Benzodiazepinas/efeitos adversos , Qualidade de Vida/psicologia , Esquizofrenia/tratamento farmacológico , Psicologia do Esquizofrênico , Administração Oral , Adulto , Benzodiazepinas/uso terapêutico , Glicemia , Peso Corporal/efeitos dos fármacos , Colesterol/sangue , Feminino , Hemoglobinas Glicadas/metabolismo , Humanos , Masculino , Pessoa de Meia-Idade , Olanzapina , Escalas de Graduação Psiquiátrica/estatística & dados numéricos , Esquizofrenia/metabolismo , Comprimidos/uso terapêutico , Triglicerídeos/sangue
3.
Expert Rev Neurother ; 11(10): 1389-97, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21955196

RESUMO

The aim of this study was to evaluate the efficacy and safety of ramelteon 4, 8, 16 or 32 mg and placebo in Japanese patients with chronic insomnia using a randomized, double-blind, five-period crossover design. A total of 65 Japanese patients with chronic primary insomnia received ramelteon or placebo for two nights each in sleep laboratories. Changes in sleep parameters were assessed objectively by polysomnography and subjectively by postsleep questionnaires. Safety and tolerability was evaluated by assessment of the occurrence of adverse events, next-day residual effects and laboratory and ECG investigations. Ramelteon 8 and 32 mg significantly shortened the mean latency to persistent sleep in comparison with placebo, and there was a statistically significant trend for linear dose-response for this sleep parameter. Overall changes in sleep architecture were modest (<3% changes vs placebo), with increases in stage 1 and decreases in stage 3/4. Ramelteon was well tolerated, the most common adverse effect being somnolence, which was similar to placebo at doses up to 8 mg, but increased with higher doses. Next-day residual effects occurred no more frequently with ramelteon at any dose than with placebo. When compared with sleep latency data from a similarly-designed US study, there was no evidence of any ethnic differences in the efficacy of ramelteon between Japanese and US patients. Overall, ramelteon 8 mg showed the most favorable balance between sleep-promoting effects and tolerability. The unique efficacy profile of ramelteon, promoting sleep initiation without affecting other sleep parameters, may be due to its circadian shifting effect.


Assuntos
Hipnóticos e Sedativos/uso terapêutico , Indenos/uso terapêutico , Distúrbios do Início e da Manutenção do Sono/tratamento farmacológico , Adulto , Povo Asiático , Estudos Cross-Over , Relação Dose-Resposta a Droga , Método Duplo-Cego , Esquema de Medicação , Feminino , Humanos , Hipnóticos e Sedativos/efeitos adversos , Hipnóticos e Sedativos/farmacocinética , Hipnóticos e Sedativos/farmacologia , Indenos/efeitos adversos , Indenos/farmacocinética , Indenos/farmacologia , Masculino , Pessoa de Meia-Idade , Polissonografia , Sono/fisiologia , Distúrbios do Início e da Manutenção do Sono/fisiopatologia , Fases do Sono/efeitos dos fármacos , Fases do Sono/fisiologia , Inquéritos e Questionários , Resultado do Tratamento , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...